(Q42990080)

12 November 2017

The natural history and long-term outcomes in patients with chronic hepatitis C genotype 4 after interferon-based therapy (English)

1 reference

12 November 2017

1 reference

4

Waleed Al-hamoudi

1 reference

12 November 2017

Faleh Z Alfaleh

1

1 reference

12 November 2017

Khalid Alswat

2

1 reference

12 November 2017

Ahmed Helmy

3

1 reference

12 November 2017

Mohamed El-sharkawy

5

1 reference

12 November 2017

Mohanned Omar

6

1 reference

12 November 2017

Ahmed Shalaby

7

1 reference

12 November 2017

Mohaned A Bedewi

8

1 reference

12 November 2017

Qais Hadad

9

1 reference

12 November 2017

Safiyya M Ali

10

1 reference

12 November 2017

Ahmad Alfaleh

11

1 reference

12 November 2017

Ayman A Abdo

12

1 reference

12 November 2017

15 March 2013

1 reference

12 November 2017

1 reference

12 November 2017

33

1 reference

12 November 2017

6

1 reference

12 November 2017

871-883

1 reference

HCV natural history: the retrospective and prospective in perspective

12 November 2017

1 reference

Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study

21 January 2018

1 reference

Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial.

21 January 2018

1 reference

Race, insulin resistance and hepatic steatosis in chronic hepatitis C.

21 January 2018

1 reference

Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study

21 January 2018

1 reference

Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression

21 January 2018

1 reference

Natural history and predictors of disease severity in chronic hepatitis C.

21 January 2018

1 reference

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

Effect of hepatitis C virus and its treatment on survival

21 January 2018

1 reference

21 January 2018

1 reference

Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study

21 January 2018

1 reference

Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data

21 January 2018

1 reference

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

21 January 2018

1 reference

Hepatitis C genotype 4: What we know and what we don't yet know.

21 January 2018

1 reference

Management of hepatitis C virus genotype 4: recommendations of an international expert panel.

21 January 2018

1 reference

Prevalence of antibody to hepatitis C virus among Saudi Arabian children: a community-based study

21 January 2018

1 reference

Treatment of chronic hepatitis C genotype IV with interferon-ribavirin combination in Saudi Arabia: a multicentre study

21 January 2018

1 reference

Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4.

21 January 2018

1 reference

A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt

21 January 2018

1 reference

Hepatitis C virus genotypes in patients with chronic liver disease and haemodialysis patients from Saudi Arabia

21 January 2018

1 reference

Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4

21 January 2018

1 reference

Sustained virologic response to peginterferon alpha-2a and ribavirin in 335 patients with chronic hepatitis C: a tertiary care center experience

21 January 2018

1 reference

Non-invasive evaluation of liver cirrhosis using ultrasound

21 January 2018

1 reference

How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?

21 January 2018

1 reference

Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C.

21 January 2018

1 reference

Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis

21 January 2018

1 reference

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

21 January 2018

1 reference

Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

21 January 2018

1 reference

Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C.

21 January 2018

1 reference

Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection

21 January 2018

1 reference

Validation of three noninvasive laboratory variables to predict significant fibrosis and cirrhosis in patients with chronic hepatitis C in Saudi Arabia

21 January 2018

1 reference

Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus

21 January 2018

1 reference

Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.

21 January 2018

1 reference

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

21 January 2018

1 reference

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

21 January 2018

1 reference

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

21 January 2018

1 reference

Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin

21 January 2018

1 reference

Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients

21 January 2018

1 reference

Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.

21 January 2018

1 reference

Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection

21 January 2018

1 reference

Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis

21 January 2018

1 reference

Screening for hepatitis C virus infection: a review of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.

21 January 2018

1 reference

Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease

21 January 2018

1 reference

Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.12127

1 reference

12 November 2017

1 reference